ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$37.52
+1.10%Oct 21, 2026, 14:24 UTC
Roivant said it will seek expanded FDA approval for Lisraya in the first half of 2027.
Source:Oct 21, 2026, 12:05 UTC
Roivant and its spinout Priovant reported that Lisraya was more effective than placebo in treating non-infectious uveitis in two Phase 3 trials involving 371 patients.
Source:Oct 21, 2026, 11:00 UTC
Immunovant announced that it will report financial results for the fiscal second quarter ended September 30, 2026, on November 9, 2026, before the market opens.
Source:Oct 21, 2026, 11:00 UTC
Roivant Sciences Ltd. announced that it will host a conference call and webcast on November 9, 2026, to report second-quarter financial results and provide a business update.
Sep 10, 2026, 10:30 UTC
Roivant reported strong efficacy for its pipeline drug mosliciguat in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Source:Sep 8, 2026, 10:11 UTC
Roivant Sciences announced that its experimental lung disease drug met the main goal in a mid-stage study, causing its shares to surge 21.1% in pre-market trading.
Source:Sep 7, 2026, 13:56 UTC
Roivant and its subsidiary Pulmovant announced that results from the Phase 2 PHocus study of Mosliciguat in PH-ILD will be presented at the ERS International Congress 2026 on September 8, 2026.
Aug 28, 2026, 13:46 UTC
Roivant and Priovant Therapeutics launched their newly approved rare disease drug Lisraya at a list price of $35,000 for a 30-day supply on Friday.
Source:Aug 6, 2026, 11:00 UTC
Roivant is on track to launch brepocitinib for dermatomyositis by the end of September 2026.
Aug 6, 2026, 11:00 UTC
Roivant reported financial results for the first quarter ended June 30, 2026, with consolidated cash of $3.9 billion as of that date.
Source:Aug 6, 2026, 00:00 UTC
Roivant Sciences Ltd. repurchased 7.3 million shares of its common stock for approximately $208.7 million during Q1 2026.